Hims & Hers Bets On Hormonal Health To Revive Investor Confidence

Core Insights - Hims & Hers Health Inc. has launched a new category in men's health, focusing on affordable and personalized treatment plans for low testosterone, addressing an estimated 20 million men in the U.S. who struggle with this condition [1] Group 1: New Product Offerings - The new offerings aim to enhance the company's core sexual health services and target an underserved market, especially as sales of its weight-loss drug have slowed [2] - In 2026, Hims & Hers plans to introduce an exclusive branded oral testosterone through a collaboration with Marius Pharmaceuticals, which specializes in testosterone therapy [3] - The company will also provide tailored doses of compounded enclomiphene and a dual-action treatment combining enclomiphene and tadalafil for men experiencing sexual symptoms [6] Group 2: Pricing and Accessibility - Pricing for the new treatment plans will vary, with a three-month option costing approximately $199 per month, while five- and ten-month plans will be available for $139 and $99 monthly, respectively [5] - Customers will start with an at-home blood test, receiving results in days, and then work with licensed providers to determine their treatment plans [7] Group 3: Strategic Expansion - Hims & Hers has acquired an at-home lab testing facility, Sigmund, to support at-home blood draws and comprehensive testing, which will enhance its ability to offer personalized treatments [8] - This acquisition is expected to accelerate the company's expansion into new clinical categories, including low testosterone and support for perimenopausal and menopausal women [9] Group 4: Market Performance - Following the announcement, Hims & Hers Health shares increased by 5.99% to $50.65, trading within a 52-week range of $13.70 to $72.98 [9]